LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-231 | HG-6-64-01 | 10.0 | uM | LJP6 | 2 | M01 | 72 | hr | 868 | 452 | 3486 | 0.1297 | -0.1589 |
| MDA-MB-231 | HG-6-64-01 | 10.0 | uM | LJP6 | 3 | M01 | 72 | hr | 868 | 618 | 3486 | 0.1773 | -0.0955 |
| MDA-MB-231 | WH-4-025 | 10.0 | uM | LJP5 | 1 | O07 | 72 | hr | 868 | 724 | 3486 | 0.2077 | -0.0550 |
| MDA-MB-231 | WH-4-025 | 10.0 | uM | LJP5 | 2 | O07 | 72 | hr | 868 | 720 | 3486 | 0.2065 | -0.0566 |
| MDA-MB-231 | WH-4-025 | 10.0 | uM | LJP5 | 3 | O07 | 72 | hr | 868 | 825 | 3486 | 0.2366 | -0.0165 |
| MDA-MB-231 | WZ-4-145 | 10.0 | uM | LJP6 | 1 | J19 | 72 | hr | 868 | 1096 | 3486 | 0.3144 | 0.0870 |
| MDA-MB-231 | WZ-4-145 | 10.0 | uM | LJP6 | 2 | J19 | 72 | hr | 868 | 946 | 3486 | 0.2713 | 0.0297 |
| MDA-MB-231 | WZ-4-145 | 10.0 | uM | LJP6 | 3 | J19 | 72 | hr | 868 | 791 | 3486 | 0.2269 | -0.0295 |
| MDA-MB-231 | XMD16-144 | 10.0 | uM | LJP5 | 1 | M07 | 72 | hr | 868 | 820 | 3486 | 0.2352 | -0.0184 |
| MDA-MB-231 | XMD16-144 | 10.0 | uM | LJP5 | 2 | M07 | 72 | hr | 868 | 996 | 3486 | 0.2857 | 0.0488 |
| MDA-MB-231 | XMD16-144 | 10.0 | uM | LJP5 | 3 | M07 | 72 | hr | 868 | 958 | 3486 | 0.2748 | 0.0343 |
| MDA-MB-231 | Brivanib | 10.0 | uM | LJP5 | 1 | P13 | 72 | hr | 868 | 2066 | 3486 | 0.5926 | 0.4575 |
| MDA-MB-231 | Brivanib | 10.0 | uM | LJP5 | 2 | P13 | 72 | hr | 868 | 2426 | 3486 | 0.6959 | 0.5950 |
| MDA-MB-231 | Brivanib | 10.0 | uM | LJP5 | 3 | P13 | 72 | hr | 868 | 2231 | 3486 | 0.6399 | 0.5205 |
| MDA-MB-231 | Buparlisib | 10.0 | uM | LJP5 | 1 | H01 | 72 | hr | 868 | 575 | 3486 | 0.1649 | -0.1120 |
| MDA-MB-231 | Buparlisib | 10.0 | uM | LJP5 | 2 | H01 | 72 | hr | 868 | 692 | 3486 | 0.1985 | -0.0673 |
| MDA-MB-231 | Buparlisib | 10.0 | uM | LJP5 | 3 | H01 | 72 | hr | 868 | 716 | 3486 | 0.2054 | -0.0581 |
| MDA-MB-231 | BX-912 | 10.0 | uM | LJP5 | 1 | L19 | 72 | hr | 868 | 1192 | 3486 | 0.3419 | 0.1237 |
| MDA-MB-231 | BX-912 | 10.0 | uM | LJP5 | 2 | L19 | 72 | hr | 868 | 1434 | 3486 | 0.4113 | 0.2161 |
| MDA-MB-231 | BX-912 | 10.0 | uM | LJP5 | 3 | L19 | 72 | hr | 868 | 1463 | 3486 | 0.4196 | 0.2272 |
| MDA-MB-231 | Canertinib | 10.0 | uM | LJP6 | 1 | H07 | 72 | hr | 868 | 420 | 3486 | 0.1205 | -0.1712 |
| MDA-MB-231 | Canertinib | 10.0 | uM | LJP6 | 2 | H07 | 72 | hr | 868 | 734 | 3486 | 0.2105 | -0.0512 |
| MDA-MB-231 | Canertinib | 10.0 | uM | LJP6 | 3 | H07 | 72 | hr | 868 | 699 | 3486 | 0.2005 | -0.0646 |
| MDA-MB-231 | Celastrol | 10.0 | uM | LJP6 | 1 | G07 | 72 | hr | 868 | 446 | 3486 | 0.1279 | -0.1612 |
| MDA-MB-231 | Celastrol | 10.0 | uM | LJP6 | 2 | G07 | 72 | hr | 868 | 345 | 3486 | 0.0990 | -0.1998 |